Key Drivers
- Gross Margin
- Liquidity Buffer
- Loss Persistence
AIAI Summary
ARQT has shifted from a speculative dermatology bet to a real commercial execution story, with ZORYVE's label expansions and 65% revenue growth supporting upside, but the investment now hinges on converting 90%+ gross margins into consistent profitability without dilution, rising spend, or execution slips.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Gross Margin
- •Liquidity Buffer
- •Loss Persistence
ARQT shows strong gross margins and solid liquidity, but persistent operating and net losses, rising leverage, and a high sales multiple indicate it still struggles to turn revenue into durable earnings or cash flow.
Price Behavior
Key Price Behavior Insights:
- •Higher lows
- •Fading momentum
- •Range-bound trade
ARQT remains constructive over the last month with a ~21% gain and higher lows, but fading momentum after the late-June peak leaves it range-bound unless it clears $26.7-$27.4.
Strong rally into late
Sentiment & News
Key News Insights:
- •Pediatric approval
- •Access expansion
- •Growth momentum
Arcutis' ZORYVE continues to gain momentum with a pediatric psoriasis FDA approval, broader patient access, and management reaffirming strong growth plus a self-sustaining financial profile.
These catalysts should strengthen ARQT's commercial outlook and adoption trajectory, supporting the stock's growth story
Similar Companies in Healthcare
Other companies in the same sector with AI ratings